Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 184Gastrointestinal 75CNS 27Genitourinary 19Head & Neck 17Tumor-Agnostic 16Breast 16Sarcoma 13Gynecologic 8Other solid neoplasm 4Other hematologic neoplasm 4Myeloid 3NET 2Endocrine 2Dermatologic 2Plasma cell 1Lymphoid 1

Conditions

Neuroendocrine Tumors 2Carcinoid Tumor 2Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Multiple Endocrine Neoplasia 1Adrenal Gland Neoplasms 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Erlotinib Hydrochloride × NET × Clear all
NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡